Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, announced a corporate overview presentation at the H.C.

Rhea-AI Summary

Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, announced a corporate overview presentation at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11, 2021, on the company’s website, www.soleno.life. Soleno is focused on developing novel therapeutics for rare diseases, with its lead candidate, DCCR, targeting Prader-Willi Syndrome.

Argus Session date unavailable

+4.15% session move Open Argus

Details

News Market Reaction – SLNO

The recorded move for SLNO in the trading session of this news was +4.15%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Soleno Therapeutics present at the H.C. Wainwright Virtual BioConnect 2021 Conference?

Soleno Therapeutics will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021.

Where can I watch the Soleno Therapeutics presentation?

The presentation will be available on-demand in the Investors section of Soleno Therapeutics' website starting January 11, 2021.

What is Soleno Therapeutics' lead candidate for rare diseases?

Soleno Therapeutics' lead candidate is Diazoxide Choline Controlled-Release (DCCR) tablets for Prader-Willi Syndrome.

What is the focus of Soleno Therapeutics?

Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases.

What is the stock symbol for Soleno Therapeutics?

The stock symbol for Soleno Therapeutics is SLNO.